Century Therapeutics (IPSC)
Market Price (5/30/2026): $2.4 | Market Cap: $464.3 MilSector: Health Care | Industry: Biotechnology
Century Therapeutics (IPSC)
Market Price (5/30/2026): $2.4Market Cap: $464.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Weak multi-year price returns2Y Excs Rtn is -65%, 3Y Excs Rtn is -111% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -108 Mil Stock price has recently run up significantly6M Rtn6 month market price return is 349%, 12M Rtn12 month market price return is 340% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -27% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.69 Key risksIPSC key risks include [1] a critical dependence on the successful clinical advancement and commercialization of its lead candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -65%, 3Y Excs Rtn is -111% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -108 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 349%, 12M Rtn12 month market price return is 340% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -27% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.69 |
| Key risksIPSC key risks include [1] a critical dependence on the successful clinical advancement and commercialization of its lead candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Century Therapeutics (IPSC) stock has gained about 30% since 1/31/2026 because of the following key factors:
1. Strengthened Financial Position and Extended Cash Runway: Century Therapeutics successfully completed an oversubscribed $135 million private placement financing in January 2026, significantly boosting its financial reserves. This influx of capital increased cash, cash equivalents, and marketable securities to $217.0 million as of March 31, 2026, extending the company's projected cash runway into the first quarter of 2029.
2. Advancement of Key Pipeline Programs: The company made substantial progress with its induced pluripotent stem cell (iPSC)-derived cell therapy pipeline. CNTY-813, a lead program for type 1 diabetes, remains on track for an Investigational New Drug (IND) submission in the fourth quarter of 2026, with initial clinical data expected in the second half of 2027. Additionally, CNTY-308, a CD19-targeted CAR-iT cell therapy, is slated to enter clinical testing in 2026. The upcoming oral presentation of CNTY-813 preclinical data at the American Diabetes Association Scientific Sessions in June 2026 further highlighted pipeline momentum.
Show more
Stock Movement Drivers
Fundamental Drivers
The 28.9% change in IPSC stock from 1/31/2026 to 5/29/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.90 | 2.45 | 28.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 113 | 0 | |
| P/S Multiple | 1.4 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 86 | 193 | -55.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/29/2026| Return | Correlation | |
|---|---|---|
| IPSC | 28.9% | |
| Market (SPY) | 9.6% | 42.3% |
| Sector (XLV) | -3.0% | 21.6% |
Fundamental Drivers
The 320.2% change in IPSC stock from 10/31/2025 to 5/29/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.58 | 2.45 | 320.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 114 | 0 | |
| P/S Multiple | 0.4 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 86 | 193 | -55.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| IPSC | 320.2% | |
| Market (SPY) | 11.5% | 30.7% |
| Sector (XLV) | 4.5% | 7.0% |
Fundamental Drivers
The 352.4% change in IPSC stock from 4/30/2025 to 5/29/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.54 | 2.45 | 352.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 0 | |
| P/S Multiple | 7.0 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 85 | 193 | -55.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| IPSC | 352.4% | |
| Market (SPY) | 38.0% | 28.4% |
| Sector (XLV) | 8.3% | 15.2% |
Fundamental Drivers
The -21.7% change in IPSC stock from 4/30/2023 to 5/29/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.13 | 2.45 | -21.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 0 | |
| P/S Multiple | 35.1 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 58 | 193 | -69.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/29/2026| Return | Correlation | |
|---|---|---|
| IPSC | -21.7% | |
| Market (SPY) | 89.0% | 25.7% |
| Sector (XLV) | 17.7% | 23.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IPSC Return | -31% | -68% | -35% | -70% | -2% | 140% | -90% |
| Peers Return | -7% | 32% | 41% | -1% | 2% | 5% | 83% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| IPSC Win Rate | 29% | 25% | 17% | 33% | 42% | 80% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 67% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| IPSC Max Drawdown | - | -70% | -75% | -81% | -65% | -37% | |
| Peers Max Drawdown | -27% | -19% | -12% | -23% | -29% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ALPS, AVLN, DFTX, EIKN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/29/2026 (YTD)
How Low Can It Go
| Event | IPSC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -48.7% | -18.8% |
| % Gain to Breakeven | 94.9% | 23.1% |
| Time to Breakeven | 254 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -33.9% | -7.8% |
| % Gain to Breakeven | 51.3% | 8.5% |
| Time to Breakeven | 527 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -58.2% | -9.5% |
| % Gain to Breakeven | 139.1% | 10.5% |
| Time to Breakeven | 45 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -37.6% | -6.7% |
| % Gain to Breakeven | 60.2% | 7.1% |
| Time to Breakeven | 214 days | 31 days |
In The Past
Century Therapeutics's stock fell -48.7% during the 2025 US Tariff Shock. Such a loss loss requires a 94.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | IPSC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -48.7% | -18.8% |
| % Gain to Breakeven | 94.9% | 23.1% |
| Time to Breakeven | 254 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -33.9% | -7.8% |
| % Gain to Breakeven | 51.3% | 8.5% |
| Time to Breakeven | 527 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -58.2% | -9.5% |
| % Gain to Breakeven | 139.1% | 10.5% |
| Time to Breakeven | 45 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -37.6% | -6.7% |
| % Gain to Breakeven | 60.2% | 7.1% |
| Time to Breakeven | 214 days | 31 days |
In The Past
Century Therapeutics's stock fell -48.7% during the 2025 US Tariff Shock. Such a loss loss requires a 94.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Century Therapeutics (IPSC)
AI Analysis | Feedback
Here are 1-3 brief analogies for Century Therapeutics (IPSC):
- Like a more advanced version of CAR-T cell therapy companies such as Novartis or Gilead, but focusing on creating universal, 'off-the-shelf' treatments instead of patient-specific ones.
- Like a Moderna or BioNTech for cancer cell therapies, leveraging a cutting-edge iPSC platform to develop multiple 'off-the-shelf' treatments.
AI Analysis | Feedback
- CNTY-101: An allogeneic iPSC-derived CAR-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- CNTY-103: A CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma.
- CNTY-102: A CAR-iT candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies.
- CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate being developed for acute myeloid leukemia.
- CNTY-106: A multi-specific CAR-iNK or CAR-iT candidate being developed for multiple myeloma.
AI Analysis | Feedback
Based on the provided company description, Century Therapeutics, Inc. (IPSC) is a biotechnology company primarily focused on the research and development of transformative allogeneic cell therapies for various cancers. The company's pipeline consists of several "product candidates" (such as CNTY-101, CNTY-103, CNTY-102, CNTY-104, and CNTY-106) that are in different stages of development, including clinical trials.
As a company primarily engaged in the development of future therapies, Century Therapeutics does not currently have major customers in the traditional sense, as its products have not yet received regulatory approval and are not commercially available for sale to other companies or individual patients. Therefore, at this stage, it does not sell primarily to other companies or directly to individuals.
AI Analysis | Feedback
nullAI Analysis | Feedback
Brent Pfeiffenberger, PharmD, MBA President and Chief Executive Officer
Brent Pfeiffenberger was appointed President and Chief Executive Officer of Century Therapeutics, effective December 4, 2023. Prior to joining Century, he served as Chief Operating Officer of Neogene Therapeutics. He played a central role in driving Neogene's evolution from a preclinical company to a global, clinical-stage organization, ultimately culminating in its acquisition by AstraZeneca in 2023. Before Neogene, Dr. Pfeiffenberger spent nearly two decades in leadership roles of increasing responsibility at Bristol Myers Squibb, most recently as Senior Vice President, Head of U.S. Oncology, where he oversaw business operations for a multi-billion dollar franchise. He also held several critical global leadership positions where he built, led, and expanded commercial and business operations.
Morgan Conn, PhD Chief Financial Officer
Morgan Conn was appointed Chief Financial Officer of Century Therapeutics, effective October 14, 2024. He brings over 20 years of financing and business development leadership experience in biopharma. Most recently, he served as Chief Business Officer at Pharvaris, where his responsibilities included finance operations, corporate development, capital and corporate strategy, and investor relations.
Chad Cowan, PhD Chief Scientific Officer
Chad Cowan was appointed Chief Scientific Officer of Century Therapeutics, effective October 1, 2024. Prior to joining Century, Dr. Cowan was the founder and Chief Executive Officer of Clade Therapeutics, a privately-held cell therapy company focused on iPSC-derived αβ T cell programs and technology, which was acquired by Century in April 2024. He was also a scientific founder of CRISPR Therapeutics and a founder and Chief Scientific Officer of Sana Biotechnology. Earlier, he was a member of the Broad Institute and a principal faculty member of the Harvard Stem Cell Institute, where he directed the Diabetes Disease Program and the iPS Cell Core Facility.
Greg Russotti, PhD Chief Technology and Manufacturing Officer
Greg Russotti currently serves as Chief Technology and Manufacturing Officer at Century Therapeutics, a role he assumed in December 2023. He previously served as interim Chief Executive Officer from April 2023 to December 2023 and as Chief Technology Officer since January 2020. Before joining Century, Dr. Russotti was Vice President of Cell Therapy Development and Operations at Celgene. At Celgene, he guided chemistry, manufacturing, and controls efforts for five different cell therapy products to clinical-stage development. He was also a leader in establishing in-house clinical manufacturing at Celgene and in building Celgene's first commercial CAR T manufacturing facility. Prior to Celgene, Dr. Russotti spent 12 years at Merck Research Laboratories.
AI Analysis | Feedback
Key Risks to Century Therapeutics (IPSC)
- Clinical Development and Regulatory Approval Risk: As a biotechnology company with all product candidates in development, Century Therapeutics faces significant risks related to the success of its clinical trials and the ability to obtain regulatory approvals. The failure of any lead product candidate, particularly CNTY-101, to demonstrate safety and efficacy in clinical trials, or to meet regulatory requirements, would have a material adverse impact on the company. The development of novel allogeneic, iPSC-derived cell therapies involves complex biological processes and presents unique challenges that can lead to unexpected delays or setbacks in clinical progression and regulatory pathways.
- Intense Competition and Market Adoption: Century Therapeutics operates in a highly competitive landscape for oncology treatments, specifically in the rapidly evolving field of cell therapies for solid tumors and hematological malignancies. Other pharmaceutical and biotechnology companies, including larger, well-established players, are developing or have already commercialized CAR-T and other cell therapies. Even if its product candidates are clinically successful, Century Therapeutics will need to compete effectively based on factors such as efficacy, safety, manufacturing capabilities, and cost. Furthermore, market adoption and favorable reimbursement policies for its novel iPSC-derived therapies are critical and uncertain.
- Manufacturing Complexity and Technology-Specific Challenges: The development and commercialization of allogeneic iPSC-derived cell therapies involve complex manufacturing processes that are difficult to scale, costly, and require specialized expertise and facilities. Any issues related to manufacturing consistency, quality control, or supply chain logistics could significantly delay product development or commercialization. Additionally, as a relatively nascent technology, the long-term safety, immunogenicity, and potential for tumorigenicity associated with iPSC-derived cells, while being actively researched and mitigated, represent inherent technological risks that could impact regulatory approval or market acceptance.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlCentury Therapeutics' product pipeline targets several significant addressable markets:
-
For relapsed, refractory B-cell lymphoma (CNTY-101 and CNTY-102): The global B-cell lymphoma market size was valued at approximately USD 5.08 billion in 2024 and is projected to reach USD 10 billion by 2034. The U.S. B-cell lymphoma market size was approximately USD 1.39 billion in 2024 and is projected to reach USD 2.78 billion by 2034. More specifically, the market for Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) is estimated at USD 1.61 billion in 2025 and is expected to reach USD 2.16 billion by 2032. North America is estimated to hold a dominant position in the R/r DLBCL market, with 39.1% of the market share in 2025.
-
For recurrent glioblastoma (CNTY-103): The global glioblastoma multiforme treatment market was valued at USD 3.6 billion in 2024 and is expected to grow to USD 8.3 billion in 2034. Another report indicates a global market size of USD 4.04 billion in 2025, projected to reach USD 7.87 billion by 2033. The U.S. glioblastoma multiforme treatment market accounted for USD 1.4 billion in 2024.
-
For acute myeloid leukemia (CNTY-104): The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030. Other projections estimate the global market at USD 3.91 billion in 2025, projected to reach USD 9.79 billion by 2034. North America dominated the global market with a revenue share of 37.6% in 2024. The U.S. acute myeloid leukemia treatment market accounted for 90.9% of the North American market in 2024.
-
For multiple myeloma (CNTY-106): The global multiple myeloma market size was valued at USD 29.24 billion in 2025 and is projected to grow to USD 44.19 billion by 2034. Another source estimates the global market at USD 27.75 billion in 2024, anticipated to reach USD 49.89 billion by 2034. North America dominated the multiple myeloma market with a market share of 58.28% in 2025. The total multiple myeloma market size in the U.S. was around USD 14,300 million in 2023.
AI Analysis | Feedback
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company focused on developing allogeneic induced pluripotent stem cells (iPSC)-derived cell therapies for autoimmune diseases and cancer. While the company is in a pre-revenue stage regarding product sales, its future revenue growth over the next 2-3 years is primarily expected to be driven by milestone payments from collaborations and the advancement of its key pipeline candidates. Here are 3-5 expected drivers of future revenue growth for Century Therapeutics: * Advancement and Positive Clinical Data for CNTY-101 in Autoimmune Diseases: The progression of CNTY-101, an iPSC-derived CAR-iNK cell therapy, in clinical trials for autoimmune diseases, particularly systemic lupus erythematosus (SLE), is a significant driver. Initial clinical data from the Phase 1 CALiPSO-1 trial for CNTY-101 in B-cell-mediated autoimmune diseases is anticipated by the end of 2025. Positive results from these trials could trigger milestone payments from current or future collaborators and enhance the company's attractiveness for new partnerships. * Progress of CNTY-813 for Type 1 Diabetes: CNTY-813, a beta islet cell therapy program aiming for a functional cure for type 1 diabetes, is a high-priority program for Century Therapeutics. The planned submission of an Investigational New Drug (IND) application in the fourth quarter of 2026 and the anticipation of initial clinical data in the second half of 2027 represent critical milestones. Successful advancement through these stages could lead to significant collaboration revenue through milestone payments. * Clinical Entry of CNTY-308 for B-cell-Mediated Diseases: CNTY-308, a CD19-targeted CAR-iT cell therapy, is on track to enter the clinic in 2026. The initiation of clinical trials for this candidate is a key development that can attract new collaborations or unlock milestone payments from existing agreements, thereby contributing to future revenue. * New Strategic Collaborations and Licensing Agreements: While a substantial collaboration revenue in 2025 was described as a "one-time event" related to a Bristol-Myers Squibb agreement, Century Therapeutics continues to rely on external funding and partnerships. The successful progression of its pipeline programs is expected to position the company for new strategic collaborations or the expansion of existing ones. These agreements typically include upfront payments, development milestone payments, and potential licensing fees, which would be crucial revenue drivers in the coming years.AI Analysis | Feedback
Capital Allocation Decisions for Century Therapeutics (IPSC)
Share Issuance
- Century Therapeutics launched in July 2019 with $250 million in initial financing commitments, which represented a significant share issuance to its founding investors.
- In March 2021, the company completed a $160 million Series C financing round.
- Century Therapeutics completed an oversubscribed $135 million private placement, which was reported in March 2026 to have extended its cash runway into the first quarter of 2029.
Inbound Investments
- Upon emerging from stealth mode in July 2019, Century Therapeutics secured $250 million in initial financing commitments from key partners, including Bayer, Versant Ventures, and Fujifilm Cellular Dynamics Inc. (FCDI).
- In March 2021, the company raised $160 million through a Series C financing round, led by Casdin Capital and involving a syndicate of twelve investors.
- A recent oversubscribed private placement brought in $135 million, extending Century Therapeutics' cash runway into the first quarter of 2029.
Outbound Investments
- In April 2024, Century Therapeutics acquired Clade Therapeutics for approximately $35 million in upfront consideration, paid in a mix of cash and stock, with a potential additional $10 million upon achieving a clinical milestone. This acquisition was intended to enhance Century's iPSC platform and expand its pipeline.
- In June 2020, Century Therapeutics acquired Empirica Therapeutics to leverage its expertise in iPSC-derived allogeneic cell therapies for glioblastoma (GBM).
Capital Expenditures
- In the third quarter of 2025, Century Therapeutics invested $195K in capital expenditures, primarily directed towards funding long-term assets and infrastructure.
- For the full year 2025, the company's capital expenditures amounted to $848K.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Century Therapeutics Earnings Notes | 12/16/2025 | |
| Would You Still Hold Century Therapeutics Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to IPSC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 17.52 |
| Mkt Cap | 1.6 |
| Rev LTM | 0 |
| Op Inc LTM | -151 |
| FCF LTM | -120 |
| FCF 3Y Avg | -101 |
| CFO LTM | -120 |
| CFO 3Y Avg | -99 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -45.0% |
| Rev Chg 3Y Avg | 1,356.6% |
| Rev Chg Q | -46.1% |
| QoQ Delta Rev Chg LTM | -49.1% |
| Op Inc Chg LTM | -69.8% |
| Op Inc Chg 3Y Avg | -42.7% |
| Op Mgn LTM | 38.2% |
| Op Mgn 3Y Avg | 24.1% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 34.7% |
| CFO/Rev 3Y Avg | 21.5% |
| FCF/Rev LTM | 30.4% |
| FCF/Rev 3Y Avg | 17.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.6 |
| P/S | 9.3 |
| P/Op Inc | -2.8 |
| P/EBIT | -2.8 |
| P/E | -2.8 |
| P/CFO | -3.4 |
| Total Yield | -15.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -56.0% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 8.6% |
| 3M Rtn | -6.2% |
| 6M Rtn | 0.4% |
| 12M Rtn | -1.2% |
| 3Y Rtn | -11.0% |
| 1M Excs Rtn | 2.3% |
| 3M Excs Rtn | -16.4% |
| 6M Excs Rtn | -11.2% |
| 12M Excs Rtn | -29.7% |
| 3Y Excs Rtn | -94.0% |
Price Behavior
| Market Price | $2.45 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 06/18/2021 | |
| Distance from 52W High | -16.7% | |
| 50 Days | 200 Days | |
| DMA Price | $2.28 | $1.39 |
| DMA Trend | up | up |
| Distance from DMA | 7.3% | 75.7% |
| 3M | 1YR | |
| Volatility | 76.5% | 98.3% |
| Downside Capture | 287.62 | 190.10 |
| Upside Capture | 202.89 | 310.21 |
| Correlation (SPY) | 44.4% | 31.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.62 | 2.37 | 2.42 | 2.83 | 2.19 | 1.50 |
| Up Beta | 3.08 | 3.68 | 2.38 | 2.16 | 1.41 | 0.93 |
| Down Beta | -1.88 | -0.17 | -0.71 | 4.44 | 3.12 | 1.76 |
| Up Capture | 247% | 219% | 373% | 972% | 808% | 416% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 11 | 19 | 28 | 63 | 122 | 328 |
| Down Capture | 1426% | 253% | 278% | 114% | 140% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 22 | 32 | 56 | 123 | 403 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IPSC | |
|---|---|---|---|---|
| IPSC | 344.0% | 98.3% | 1.94 | - |
| Sector ETF (XLV) | 15.8% | 14.6% | 0.78 | 13.6% |
| Equity (SPY) | 30.3% | 11.8% | 1.94 | 30.8% |
| Gold (GLD) | 37.5% | 26.7% | 1.17 | 7.4% |
| Commodities (DBC) | 39.6% | 18.8% | 1.63 | -5.2% |
| Real Estate (VNQ) | 12.5% | 13.1% | 0.64 | 7.6% |
| Bitcoin (BTCUSD) | -31.8% | 41.6% | -0.81 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IPSC | |
|---|---|---|---|---|
| IPSC | -35.9% | 84.1% | -0.17 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 24.1% |
| Equity (SPY) | 14.3% | 17.0% | 0.66 | 27.5% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 7.3% |
| Commodities (DBC) | 10.2% | 19.4% | 0.41 | 0.4% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 23.7% |
| Bitcoin (BTCUSD) | 14.6% | 54.6% | 0.46 | 17.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IPSC | |
|---|---|---|---|---|
| IPSC | -19.9% | 84.1% | -0.17 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 24.1% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 27.5% |
| Gold (GLD) | 13.3% | 16.0% | 0.69 | 7.3% |
| Commodities (DBC) | 7.3% | 17.9% | 0.33 | 0.4% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 23.7% |
| Bitcoin (BTCUSD) | 67.0% | 66.9% | 1.06 | 17.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 5/29/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/13/2026 | -0.4% | -7.4% | |
| 3/12/2026 | -8.4% | -15.8% | -17.6% |
| 11/13/2025 | -17.5% | -8.2% | 1.5% |
| 8/14/2025 | 2.1% | -1.6% | -9.6% |
| 5/15/2025 | 8.2% | 11.0% | 12.7% |
| 3/19/2025 | -5.7% | -4.6% | -6.7% |
| 1/13/2025 | -2.0% | -8.2% | -26.2% |
| 11/5/2024 | 5.6% | 16.7% | 14.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 8 | 5 |
| # Negative | 14 | 13 | 15 |
| Median Positive | 5.6% | 3.4% | 12.7% |
| Median Negative | -1.9% | -8.2% | -14.2% |
| Max Positive | 15.1% | 16.7% | 48.7% |
| Max Negative | -17.5% | -18.8% | -30.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/19/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
Recent Forward Guidance
Updated 5/28/2026Latest: Q1 2026 Earnings Reported 5/13/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 IND Submission (CNTY-813) | |||||||
| 2027 Initial Clinical Data (CNTY-813) | |||||||
| 2026 Clinical Trial Initiation (CNTY-308) | |||||||
| 2029 Cash Runway | Affirmed | Guidance: 0 for Q1 2029 | |||||
Prior: Q4 2025 Earnings Reported 3/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2029 Cash Runway | |||||||
Insider Activity
Updated 5/19/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Carr, Douglas | SVP Finance & Operations | Direct | Sell | 5062026 | 2.34 | 264 | 618 | 1,186,880 | Form |
| 2 | Carr, Douglas | SVP Finance & Operations | Direct | Sell | 3162026 | 2.55 | 7,043 | 17,953 | 1,293,008 | Form |
| 3 | Russotti, Gregory | See Remarks | Direct | Sell | 3162026 | 2.55 | 10,076 | 25,684 | 1,313,823 | Form |
| 4 | Russotti, Gregory | See Remarks | Direct | Sell | 3112026 | 2.54 | 479 | 1,215 | 1,332,676 | Form |
| 5 | Carr, Douglas | SVP Finance & Operations | Direct | Sell | 3112026 | 2.54 | 247 | 626 | 1,304,275 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.